Influence of O(2)-carrying plasma hemoprotein "albumin-heme" on complement system and platelet activation in vitro and physiological responses to exchange transfusion.
Recombinant human serum albumin (HSA) including the synthetic iron(II)-porphyrin (FeP), albumin-heme (HSA-FeP), is a unique O(2)-carrying plasma hemoprotein as a red blood cell substitute. We have investigated the possible influence of HSA-FeP on the complement system and platelet activation in vitro. The amounts of the serum complement titer CH(50) and terminal complement complex SC5b-9 of human blood serum, incubated with HSA-FeP (10, 20, and 40 vol %), were almost the same as those of the corresponding samples with HSA. The effect of HSA-FeP on the platelet reactivity has been demonstrated by conformational changes in the membrane glycoprotein IIb/IIIa and surface expression of an alpha-granule membrane protein P-selectin. Platelet activation in response to the ADP-stimulation was not influenced by the presence of HSA-FeP. It can be concluded that the albumin-heme solution does not facilitate the immunological reaction and platelet activation. Moreover, a 20% exchange transfusion with HSA-FeP into anesthetized rats has been performed to evaluate the circulation and blood parameters for 6 h. Time course changes in all parameters showed features identical to the control group (without infusion) and HSA group.
Komatsu
Teruyuki
T
Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan.
Huang
Yubin
Y
Wakamoto
Shinobu
S
Abe
Hideki
H
Fujihara
Mitsuhiro
M
Azuma
Hiroshi
H
Ikeda
Hisami
H
Yamamoto
Hisashi
H
Horinouchi
Hirohisa
H
Kobayashi
Koichi
K
Tsuchida
Eishun
E
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001775:Blood Circulation / Q000187:drug effects; D001784:Blood Gas Analysis; D001792:Blood Platelets / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D003165:Complement System Proteins / Q000276:immunology*; D005078:Exchange Transfusion, Whole Blood; D006339:Heart Rate / Q000187:drug effects; D006400:Hematocrit; D006420:Hemeproteins / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D010100:Oxygen / Q000378:metabolism*; D015539:Platelet Activation / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D011993:Recombinant Fusion Proteins / Q000097:blood* / Q000737:chemistry / Q000494:pharmacology*; D019087:Selectins / Q000378:metabolism; D012709:Serum Albumin / Q000737:chemistry / Q000494:pharmacology*; D000075462:Serum Albumin, Human; D013997:Time Factors
D000911:Antibodies, Monoclonal; D006420:Hemeproteins; D011993:Recombinant Fusion Proteins; D019087:Selectins; D012709:Serum Albumin; C400056:rHSA-FeP protein, human; D003165:Complement System Proteins; D010100:Oxygen; D000075462:Serum Albumin, Human